OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry’s first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presentation by Christine Vuong, Ph.D., Senior Scientist, titled “Heavy Chain-Only Transgenic Chickens Produce Human Antibodies with Robust Immune Repertoires and High-Affinity Binding.”
https://www.businesswire.com/news/home/20231214937823/en/(Photo:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.